flow semaglutide 1.0 mg (Ozempic) Reduced Kidney Events 24% in Trial π¨#FLOW: The most anticipated trial
Description
GLP-1 drugs like Semaglutide demonstrated significant weight loss benefits for patients with a BMI over 40, making them a preferred option for managing high-risk obesity cases
Published July 29, 2024
instead, it compounds your risk of serious medical emergencies and severe digestive issues
Cardiovascular outcomes trials, if initiated, would address the key data gap relative to Metformin
Before switching, do a GLP-1 cost comparison
